Health officials in Ireland moved Sunday to halt distribution of AstraZeneca’s COVID-19 vaccine, citing concerns raised by officials in Norway over a potential blood-clotting issue.

Reuters reported that Irish authorities said the move was taken out of “an abundance of caution,” while explaining that officials had reported cases of blood-clotting issues in recipients of the AstraZeneca vaccine similar to those reported by several Norwegian health workers who took the vaccine.

Similar reports have cropped up in Denmark, and Ireland joins that country alongside Norway and Iceland in deciding to halt the vaccine’s distribution. The AstraZeneca shot is not yet authorized for emergency use in the U.S.

It may be nothing, we may be overreacting and I sincerely hope that in a weeks time that we will have been accused of being overly-cautious, Ireland’s deputy health minister told RTE, an Irish broadcaster.

Hopefully we will have data to reassure us in a few short days and we will be back up and running with this,” the minister continued.

One Italian region made a similar decision Sunday, according to Reuters, after one recipient of the vaccine died.

Officials at the World Health Organization (WHO) have said that there is no clear evidence of a link between AstraZeneca’s vaccine and blood-clotting issues, a claim echoed by the company itself. The vaccine is one of several being included in the WHO-led COVAX effort to distribute doses to poorer nations.

“There will be people who have been immunized who will die of other causes. So far the preliminary data we have seen does not lead to a causal relationship,” said Mariângela Simão, a WHO deputy general.